for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ascendis Health Ltd

ASCJ.J

Latest Trade

464.00ZAc

Change

-21.00(-4.33%)

Volume

121,418

Today's Range

450.00

 - 

471.00

52 Week Range

305.00

 - 

852.00

As of on the Johannesburg Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
485.00
Open
465.00
Volume
121,418
3M AVG Volume
3.76
Today's High
471.00
Today's Low
450.00
52 Week High
852.00
52 Week Low
305.00
Shares Out (MIL)
485.50
Market Cap (MIL)
2,373.93
Forward P/E
3.49
Dividend (Yield %)
--

Latest Developments

More

Ascendis Health Says In Negotiations Over Potential Disposal Of Remedica

Ascendis Health Appoints Mark Sardi As CEO

Ascendis Health Says Disposal Of Businesses Within Biosciences Division Unconditional

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ascendis Health Ltd

Ascendis Health Limited is a health and care brands company. The Company operates through four segments: Consumer Brands, Pharma-Med, Phyto-Vet and International. Its Consumer Brands segment consists of health and personal care products sold to the public, primarily at the retail store level. It offers over the counter (OTC) medicines and consumer brands products, including vitamins and minerals, homeopathic, herbal products, dermaceuticals, functional foods, functional super foods, sports nutrition, health beverages, weight management and therapeutic cosmetics. Its Pharma-Med segment consists of the sale of prescription and selected OTC pharmaceuticals, and includes medical devices. The Phyto-Vet segment supplies health and care products to the plant and animal markets. It manufactures and supplies over 3,500 products. The International segment sells health and personal care products, prescription and selected OTC pharmaceuticals and medical devices operating in the European market.

Industry

Major Drugs

Contact Info

31 Georgian Crescent East

+27.11.0369600

http://www.ascendis.co.za/

Executive Leadership

Andrew Brian Marshall

Chairman of the Board

Kieron Futter

Chief Financial Officer, Executive Director

Marnus Sonnekus

Interim Chief Operating Officer

Cornelle Van Graan

Head of Direct Selling

A. Sims

Company Secretary

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, ZAR)

2016

3.9K

2017

6.4K

2018

7.7K

2019(E)

7.7K
EPS (ZAR)

2016

1.200

2017

1.457

2018

1.360

2019(E)

1.390
Price To Earnings (TTM)
5.12
Price To Sales (TTM)
0.31
Price To Book (MRQ)
0.34
Price To Cash Flow (TTM)
2.84
Total Debt To Equity (MRQ)
82.38
LT Debt To Equity (MRQ)
65.06
Return on Investment (TTM)
3.90
Return on Equity (TTM)
3.07

Latest News

Latest News

BRIEF-Ascendis Health HY HEPS Rises, Launches Strategic Review

* DIRECTORS HAVE ELECTED NOT TO DECLARE AN INTERIM DIVIDEND AND TO RETAIN CASH TO SETTLE DEBT OBLIGATIONS

BRIEF-Ascendis Health appoints Thomas Thomsen as CEO with effect from 1 March 2018

* ANNOUNCE APPOINTMENT OF THOMAS THOMSEN AS CHIEF EXECUTIVE OFFICER AND AS AN EXECUTIVE DIRECTOR WITH EFFECT FROM 1 MARCH 2018

BRIEF-Ascendis Health Sees ‍HY HEPS Of 52 - 55 Cents​

* SEES HY HEADLINE EARNINGS PER SHARE OF 52 - 55 CENTS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Ascendis Health announces acquisition of Kyron Laboratories Proprietary Ltd​

* ACQUISITION OF 100% OF KYRON LABORATORIES PROPRIETARY LIMITED

BRIEF-Ascendis Health announces ‍transaction update relating to acquisition of Remedica​

* TRANSACTION UPDATE RELATING TO ASCENDIS' ACQUISITION OF REMEDICA

BRIEF-Ascendis Health intends to raise about 750 mln rand in rights offering​

* COMPANY INTENDS TO RAISE APPROXIMATELY 750 MILLION RAND IN RIGHTS OFFERING

UPDATE 1-South African rand edges lower, stocks hit new record highs

* Ascendis Health leads stocks higher (Updates prices, adds stocks)

BRIEF-Ascendis Health sees full-year HEPS up 54 pct to 66 pct​

* SEES FY NORMALISED HEADLINE EARNINGS PER SHARE OF 148 - 159 CENTS, UP 22 PCT - 31 PCT

BRIEF-Ascendis says Sunwave deal to close on June 2

* Transactions are officially unconditional, thereby resulting in an effective date of 2 June 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Ascendis says to buy assets of Sunwave Pharma and NHP Pharma

* Ascendis will acquire 1.1. Core business assets of Sunwave Pharma SRL , a distribution company based in Romania,

BRIEF-Ascendis says to acquire Cipla Agrimed & Cipla Vet for 375 mln rand

* Acquisition Of 100 pct Of Cipla Agrimed Proprietary Limited And Cipla Vet Proprietary Limited

BRIEF-Ascendis sees HY HEPS between 40-43 cents

* Sees HY headline earnings per share between 40 - 43 cents Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up